Management for a Patient with Barret’s Esophagus: A Case Report

• Main Authors: Muhammad Miftahussurur, Iswan Abbas Nusi, Poernomo Boedi Setiawan, Herry Purbayu, Titong Sugihartono, Ummi Maimunah, Ulfa Kholili, Budi Widodo, Husin Thamrin, Amie Vidyani
• Format: Book Section PeerReviewed
• Language: English; English; English
• Published: SCITEPREES-Science and Technology Publications, Lda. 2017
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: http://repository.unair.ac.id/92040/1/17p.%20Management%20for%20a%20Patient%20with%20Barret%E2%80%99s%20Esophagus_%20A%20Case%20Report.pdf; http://repository.unair.ac.id/92040/2/17.%20managemenet%20patient%20barrets.pdf; http://repository.unair.ac.id/92040/5/management%20barrets.pdf; http://repository.unair.ac.id/92040/; https://www.scitepress.org/PublicationsDetail.aspx?ID=pF/Tm2EbJus=&t=1
• Institution: Universitas Airlangga

Barrett's esophagus (BE) is a displacement of the squamocolumnar border (SCJ) site to proximal to the gastroesophageal junction (GEJ) accompanied by the presence of intestinal metaplasia. BE develops when reflux-induced stomach acid destroys the squamous epithelial layer of the esophagus and this lesion heals via a metaplasia process in which the damaged squamous epithelial layer is replaced by columnar colon-type epithelium. BE prevalence in the general population is about 1.6-1.7%. Patients with gastroesophageal reflux disease (GERD) may progress to BE. This report concerns two cases of patients with Barrett's esophagus. In both these patients BE was found without dysplasia. A diagnosis was made on the basis of anamnesis, physical examination, laboratory, radiological, endoscopy and anatomical pathology. The management of BE is aimed at three main objectives: reduction of symptoms due to GERD, avoiding progression to strictures and ulcers, and preventing progression to adenocarcinom a. Both patients were given a PPI, a prokinetic and chemoprevention NSAID which achieved clinical improvement. Neither patient had ablation, photodynamic or mucosal resection. BE survival is much better than in groups without BE (5 years survival 61% vs. 28%, P = 0.001)